<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357084</url>
  </required_header>
  <id_info>
    <org_study_id>1978.00</org_study_id>
    <secondary_id>FHCRC-1978.00</secondary_id>
    <secondary_id>CDR0000488486</secondary_id>
    <nct_id>NCT00357084</nct_id>
  </id_info>
  <brief_title>Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant</brief_title>
  <official_title>A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Methotrexate and glucocorticoid therapy, such as prednisone or methylprednisolone,&#xD;
      may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell&#xD;
      transplant.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving methotrexate together with&#xD;
      glucocorticoids works in treating patients with newly diagnosed acute graft-versus-host&#xD;
      disease after donor stem cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine, within the limits of a phase II study, whether low-dose methotrexate can&#xD;
           accelerate withdrawal of glucocorticoids and decrease nonrelapsing mortality in patients&#xD;
           with newly diagnosed acute graft-versus-host disease (GVHD) who have undergone&#xD;
           nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT).&#xD;
&#xD;
        -  Determine the tolerability of low-dose methotrexate and glucocorticoids in treating&#xD;
           newly diagnosed acute GVHD in these patients.&#xD;
&#xD;
      OUTLINE: This is a cohort study. Patients receive concurrent low-dose methotrexate and a&#xD;
      glucocorticoid for treatment of acute graft-versus-host disease (GVHD).&#xD;
&#xD;
      Patients receive the first dose of methotrexate IV ≥ 12 hours before initiation of&#xD;
      glucocorticoid treatment (if glucocorticoid treatment has not been initiated) and the second&#xD;
      dose 72 hours after dose 1. Patients then receive subsequent doses of methotrexate IV or&#xD;
      orally once weekly for up to 1 year* until resolution of GVHD in the absence of recurrent&#xD;
      malignancy, refractory or chronic GVHD, administration of secondary treatment for GVHD, or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      NOTE: *Treatment with low-dose MTX may continue beyond 1 year at the discretion of the&#xD;
      managing physician.&#xD;
&#xD;
      Patients receive glucocorticoid therapy comprising prednisone or methylprednisolone IV twice&#xD;
      daily until objective evidence of improvement in GVHD manifestation. Patients with resolved&#xD;
      or significantly improved GVHD receive treatment for 10 days followed by an accelerated taper&#xD;
      for a total of 72 days of treatment in case of no flare up of GVHD during the glucocorticoid&#xD;
      taper. Patients with exacerbation or recurrence of GVHD during the accelerated taper are&#xD;
      treated for ≥ 1 week before resuming a less rapid taper. Patients who develop GVHD&#xD;
      progression or primary refractory GVHD may receive secondary systemic therapy at the&#xD;
      discretion of the managing physician.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 1 year and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 53 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients treated with a methylprednisolone-equivalent glucocorticoid dose ≤ 0.75 mg/kg on day 28 after initiation of systemic glucocorticoid therapy for acute graft-versus-host disease (GVHD)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in whom methotrexate (MTX) had to be discontinued because of toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe acute GVHD (grades III or IV)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of extensive chronic GVHD</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary systemic immunosuppressive therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative corticosteroid use over 1 year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nonrelapsing mortality at 1 year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of invasive mold infections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of recurrent/progressive malignancy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of methylprednisolone-equivalent treatment during the first 8 weeks after enrollment in patients who survive to day 56</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Newly diagnosed acute graft-versus-host disease (GVHD)&#xD;
&#xD;
          -  Has undergone nonmyeloablative allogeneic hematopoietic stem cell transplantation&#xD;
             (HSCT) from an HLA-matched related or unrelated donor ≥ 14 days ago&#xD;
&#xD;
          -  Treatment of GVHD with glucocorticoids indicated by 1 of the following criteria:&#xD;
&#xD;
               -  Initial treatment with prednisone or methylprednisolone at 2 mg/kg indicated (in&#xD;
                  the judgement of attending physician) by any of the following:&#xD;
&#xD;
                    -  Severity of GVHD requires hospitalization&#xD;
&#xD;
                    -  GVHD manifestations include symptoms other than anorexia, nausea, and&#xD;
                       vomiting&#xD;
&#xD;
                    -  GVHD begins within 2-3 weeks after HSCT&#xD;
&#xD;
                    -  GVHD manifestations progress rapidly from 1 day to the next before treatment&#xD;
&#xD;
               -  Initial treatment with prednisone or methylprednisolone at 1 mg/kg did not&#xD;
                  produce adequate clinical improvement within the first 4 days (in the judgement&#xD;
                  of attending physician)&#xD;
&#xD;
          -  No pleural effusion or ascites (i.e., free-flowing fluid by lateral decubitus views)&#xD;
&#xD;
               -  Mere blunting of costo-phrenic angles on a posterior anterior chest x-ray is not&#xD;
                  sufficient&#xD;
&#xD;
          -  No GVHD after donor lymphocyte infusion&#xD;
&#xD;
          -  No hallmarks of chronic GVHD&#xD;
&#xD;
          -  No bronchiolitis obliterans&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No severe mucositis (grade 3 or 4) indicated by erythema, edema, or ulcerations&#xD;
             requiring hydration, parenteral nutritional support, or intubation or resulting in&#xD;
             aspiration pneumonia&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 2 times upper limit of normal (ULN) (unless abnormality attributable to&#xD;
             GVHD)&#xD;
&#xD;
          -  AST and ALT ≤ 2 times ULN (unless abnormality attributable to GVHD)&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior prednisone or methylprednisolone at 2 mg/kg for &gt; 72 hours or at 1 mg/kg for&#xD;
             &gt; 96 hours&#xD;
&#xD;
          -  Concurrent topical therapy, including psoralen and ultraviolet A irradiation (PUVA),&#xD;
             glucocorticoid creams, oral beclomethasone dipropionate, topical azathioprine, or&#xD;
             ophthalmic glucocorticoids allowed&#xD;
&#xD;
          -  No other concurrent treatment for GVHD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco B. Mielcarek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>September 10, 2010</last_update_submitted>
  <last_update_submitted_qc>September 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Marco B. Mielcarek</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>graft versus host disease</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

